Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol
BiotechnologyInvestor Relations

Molecular Partners Provides Regulatory Update of European and Japanese Filings of Abicipar Pegol

July 20, 2020 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / July 20, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that Allergan, an AbbVie company, has informed Molecular Partners of their intent to withdraw application filings with both the European Medicines Agency (EMA) and the Japanese Regulatory Agency (PMDA) for abicipar...

Read more
Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering
BiotechnologyFinancing

Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering

July 17, 2020 9:40 AM

IRVINE, CA / ACCESSWIRE / July 17, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately $5.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable...

Read more
Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited
BiotechnologyMergers and Acquisitions

Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited

July 17, 2020 9:15 AM

CAPE TOWN, SA / ACCESSWIRE / July 17, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective July 16th, 2020, it has signed a Memorandum of Agreement to pursue the Acquisition (the "Transaction") of Tsime Pharmaceuticals and Medicinal Supplies (Pty) Ltd ("Tsime"). Tsime will become a...

Read more
FDA Provides Positive Feedback on Tetra Bio-Pharma's Pre-Investigational New Drug Application for ARDS-003 to Be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome (ARDS)
BiotechnologyRegulatory

FDA Provides Positive Feedback on Tetra Bio-Pharma's Pre-Investigational New Drug Application for ARDS-003 to Be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome (ARDS)

July 16, 2020 8:00 AM

FDA stated that the nonclinical program was appropriate to support initiating studies in COVID-19 patients OTTAWA, CANADA / ACCESSWIRE / July 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that the U.S. Food and Drug Administration (FDA) has favorably reviewed the company's Pre-Investigational New Drug (PIND)...

Read more
Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company
BiotechnologyCompany Update

Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company

July 15, 2020 8:30 AM

JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a new,...

Read more
Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX
BiotechnologyExchange Listing Upgrade

Tetra Bio-Pharma Receives Conditional Approval to Graduate to the TSX

July 15, 2020 8:00 AM

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, ON / ACCESSWIRE / July 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has received conditional approval from the Toronto Stock Exchange (the "TSX") to graduate from the TSX Venture Exchange ("TSX-V") and list its...

Read more
Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)
BiotechnologyCompany Update

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)

July 14, 2020 6:00 AM

GOLDEN, CO / ACCESSWIRE / July 14, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR - a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science - announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®. This patient was admitted to an emergency room with classic COVID-19 symptoms in late...

Read more
Tetra Bio-Pharma Appoints Steve Edgett As A Strategic Advisor
BiotechnologyCompany Update

Tetra Bio-Pharma Appoints Steve Edgett As A Strategic Advisor

July 9, 2020 8:00 AM

OTTAWA / ACCESSWIRE / July 9, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has appointed Steve Edgett as a Strategic Advisor. Mr. Edgett will act as a special advisor to the CEO and the Board of Directors with a mandate to advise on strategic and capital markets aspects of the Company's activities and to aid in the...

Read more
Molecular Partners to Collaborate with AGC Biologics for Manufacturing of Anti-COVID-19 DARPin(R) Program
BiotechnologyInvestor Relations

Molecular Partners to Collaborate with AGC Biologics for Manufacturing of Anti-COVID-19 DARPin(R) Program

July 9, 2020 1:00 AM

Partnership secures initial clinical and commercial-scale microbial manufacturing capacity The only tri-specific antiviral protein in development, with potential best-in-class potency Clinical studies planned for Q4 2020 ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / July 9, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics,...

Read more
Completion of Name Change and Share Consolidation
BiotechnologyCompany Name ChangeCompany UpdateInvestor Relations

Completion of Name Change and Share Consolidation

July 8, 2020 3:00 PM

VANCOUVER, BC / ACCESSWIRE / July 8, 2020 / CANAM BIOTECH INC. (formerly, Hemagenetics Technologies Corp.) (the "Company") is pleased to announce that effective July 7, 2020 it has completed its name change from "Hemagenetics Technologies Corp." to "Canam Biotech Inc." and the consolidation of its issued and outstanding Common Shares on the basis of 75 pre-consolidation shares for each 1 post-consolidation share for shareholders of record as of...

Read more
Quanta Announces
BiotechnologyCompany Update

Quanta Announces "Town Hall" Style Shareholder Update for July 15, 2020 at 1:30 PM ET

July 8, 2020 2:10 PM

BURBANK, CA / ACCESSWIRE / July 8, 2020 / Quanta, Inc. (OTC PINK:QNTA), an applied sciences company based on a quantum biology platform that significantly boosts the potency and efficiency of any plant-based matter, today announced another virtual "Town Hall" style investor event, which will be broadcast live over the internet on July 15, 2020 at 1:30 PM ET / 10:30 AM PT. Eric Rice, the company's Chief Executive Officer, will lead the session...

Read more
DECN Announces Distribution Agreement Covering GenViro! Covid-19:10.5 Swift Kits and Its GenUltimate and TGB Products in India, Malaysia, Sri Lanka, Singapore, Indonesia, Thailand, Vietnam, Nepal, Bangladesh and Australia
BiotechnologyCompany Update

DECN Announces Distribution Agreement Covering GenViro! Covid-19:10.5 Swift Kits and Its GenUltimate and TGB Products in India, Malaysia, Sri Lanka, Singapore, Indonesia, Thailand, Vietnam, Nepal, Bangladesh and Australia

July 8, 2020 9:15 AM

COMPANY ALSO ANNOUNCES IT IS CURRENTLY EVALUATING ADDITIONAL AGREEMENTS FOR DISTRIBUTION OF GENVIRO! SWIFT KITS IN BRAZIL, ARGENTINA, NIGERIA AND THE PHILIPPINES, AND THAT IT HAS FILED A PROVISIONAL PATENT FOR ITS GENULTIMATE TBG PRODUCT LOS ANGELES, CA / ACCESSWIRE / July 8, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc., today announced it has entered into a written distribution...

Read more
Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies
BiotechnologyCompany Update

Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies

July 8, 2020 8:30 AM

Dyadic Now Partnered with all of the Top Four Animal Health Companies Five Fully Funded Animal Health Research Projects with Three New Relationships Announced this Year JUPITER, FL / ACCESSWIRE / July 8, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development,...

Read more
Apollo Endosurgery Announces 510k Submission for the X-Tack(TM) Endoscopic HeliX Tacking System for the Treatment of Gastrointestinal Defect Closures
BiotechnologyCompany UpdateProduct Announcements

Apollo Endosurgery Announces 510k Submission for the X-Tack(TM) Endoscopic HeliX Tacking System for the Treatment of Gastrointestinal Defect Closures

July 7, 2020 7:30 AM

AUSTIN, TX / ACCESSWIRE / July 7, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the 510k submission of the X-Tack™ Endoscopic HeliX Tacking System to the U.S. Food and Drug Administration seeking clearance for the new, through-the-scope, suture-based device designed specifically for closing defects in the lower...

Read more
Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding
BiotechnologyFinancingInvestor Relations

Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding

July 6, 2020 7:05 PM

Proceeds from the Offering will help accelerate development of the SARS-CoV-2 antiviral candidate, MP0420, as well as early stage clinical and preclinical pipeline assets ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / July 6, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, today announced that it has successfully placed...

Read more
DECN CEO Offers Open Letter on COVID-19 Testing Highlighting Needed Support for Innovation in Testing
BiotechnologyInvestor Relations

DECN CEO Offers Open Letter on COVID-19 Testing Highlighting Needed Support for Innovation in Testing

July 2, 2020 10:15 AM

CEO asks the critical question, "Why is there such a slow march to accept Novel Covid-19 testing methodologies?" LOS ANGELES, CA / ACCESSWIRE / July 2, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc., today produced an "Open Letter" outlining the need for greater and faster support for innovative solutions to the Covid-19 testing needs of the country. As a leading provider of diabetic...

Read more
Wuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional Foods
BiotechnologyPartnerships

Wuhan General Group Signs Collaborative Partnership LOI With Jugular for CBD Functional Foods

July 1, 2020 8:45 AM

MONTREAL, QC / ACCESSWIRE / July 1, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce, that effective June 30th, 2020, it has signed a letter of intent to pursue a Partnership where Jugular will support and offer its expertise to the Company in creating a specialized division within MJ Medtech...

Read more
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM)

July 1, 2020 8:05 AM

XCART technology platform is a significantly differentiated, proprietary approach to personalized CAR T therapy for the treatment of multiple tumor types of B-cell Non-Hodgkin lymphoma (NHL) Recently secured two academic collaborations to advance development of XCART Company strategically well-positioned to execute on pathway to advance the XCART platform technology through preclinical development and potentially into a Phase 1...

Read more
Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index
BiotechnologyCompany Update

Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index

June 29, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, announced today that the Company will be added to the small-cap Russell 2000® Index and the...

Read more
American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market
BiotechnologyCompany Update

American CryoStem Announces the Conversion of Debenture into Equity and Sale into the Market

June 29, 2020 7:00 AM

The debt issuance has been executed in accordance with the terms of the Debenture contained in the Company's 10-Q through the issuance of common shares in order to preserve cash available to fund ongoing operations. As the US economy improves and physicians' offices re-open the Company foresees its cGMP laboratory processing cellular samples by late summer despite the Covid-19 pandemic and its associated shutting down of the American...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?